COVID-19: Chugai’s Actemra: Roche, 3P start in the world
Chugai’s “Actemra”:
Chugai’s “Actemra” is a treatment for rheumatoid arthritis.
Removes the inflammation-causing substance “interleukin-6 (IL-6)”.
Currently, it is a strong candidate for the treatment of new corona infections.
Roche: Chugai’s parent company
We are conducting Phase 3 clinical trials in the United States and Europe.
Roche, a major Swiss pharmaceutical company, started Phase 3 clinical trials in the United States and Europe in March 2020.
[Reduced discharge period]
Evaluation items such as clinical status and mortality rate were not achieved.
On the other hand, in patients who received Actemra, the time to discharge was shortened by 8 days.
Clinical trials in the US and South Africa:
In addition, clinical trials are being conducted in the United States and South Africa, mainly for the minority races and ethnic groups who do not receive sufficient medical services.
In trials, Actemra administration reduces the likelihood of requiring mechanical ventilation.
Clinical trials in Japan:
In Japan, Phase 3 clinical trials of Actemra for critically ill inpatients are underway.
Chugai says it will decide on a domestic approval application policy based on the results of overseas tests.
New switch
Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Roche Confirms Tocilizumab (Actemra®) Failed to Meet Endpoints in the Phase 3 COVACTA Study Involving COVID-19 Associated Pneumonia